|Articles|December 7, 2021

Investigators Initiate Post-Trastuzumab Trial of GLSI-100 in Patients With Invasive Breast Cancer

Author(s)Tony Hagen

Investigators hope to duplicate promising phase 2b trial results with an experimental peptide vaccine in a population of nearly 500 patients with human epidermal growth factor receptor 2 breast cancer.

Patients who have progressed on trastuzumab, including trastuzumab biosimilars, will be enrolled in a phase 3 trial of a promising immunotherapy for the treatment of breast cancer recurrence, according to an abstract presented at the San Antonio Breast Cancer Symposium 2021.

The trial will evaluate the safety and efficacy of human epidermal growth factor receptor 2 (HER2)/neu peptide GLSI-100 in patients with residual disease or high-risk pathologic complete response (pCR) after neo-adjuvant and postoperative adjuvant anti-HER2 therapy.

GLSI-100 incorporates granulocyte-macrophage colony-stimulating factor and sargramostim, which contribute to the development of white blood cells and cells that become platelets; and GP2, which is a 9 amino acid transmembrane peptide of the HER2/neu protein. This combination is believed to stimulate an immune response targeting HER2/neu–expressing cancers.

Internal server error